• ViiV's two-drug regimen gets EU approval for HIV-1 pharmafile
    May 25, 2018
    ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the European Commission, making it the first available two-drug regimen, daily single pill solution for the type 1
PharmaSources Customer Service